[go: up one dir, main page]

MX2009001937A - Biomarcadores para el progreso de la enfermedad de alzheimer. - Google Patents

Biomarcadores para el progreso de la enfermedad de alzheimer.

Info

Publication number
MX2009001937A
MX2009001937A MX2009001937A MX2009001937A MX2009001937A MX 2009001937 A MX2009001937 A MX 2009001937A MX 2009001937 A MX2009001937 A MX 2009001937A MX 2009001937 A MX2009001937 A MX 2009001937A MX 2009001937 A MX2009001937 A MX 2009001937A
Authority
MX
Mexico
Prior art keywords
alzheimer
biomarkers
disease progression
disease
dementia
Prior art date
Application number
MX2009001937A
Other languages
English (en)
Inventor
Jonathan Benjamin Singer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009001937A publication Critical patent/MX2009001937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere en general a la prueba analítica de muestras de tejido in vitro, y más particularmente a aspectos de los polimorfismos genéticos asociados con la conversión desde el deterioro cognitivo leve hasta la demencia, por ejemplo, enfermedad de Alzheimer (AD). La invención proporciona mutaciones asociadas con la enfermedad de Alzheimer que son útiles en el diagnóstico, pronóstico, o tratamiento terapéutico de demencia, por ejemplo, enfermedad de Alzheimer.
MX2009001937A 2006-08-21 2007-08-17 Biomarcadores para el progreso de la enfermedad de alzheimer. MX2009001937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82302506P 2006-08-21 2006-08-21
PCT/US2007/076159 WO2008024677A1 (en) 2006-08-21 2007-08-17 Biomarkers for alzheimer's disease progression

Publications (1)

Publication Number Publication Date
MX2009001937A true MX2009001937A (es) 2009-04-30

Family

ID=38596184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001937A MX2009001937A (es) 2006-08-21 2007-08-17 Biomarcadores para el progreso de la enfermedad de alzheimer.

Country Status (11)

Country Link
US (1) US20100249107A1 (es)
EP (1) EP2056876A1 (es)
JP (1) JP2010501186A (es)
KR (1) KR20090041447A (es)
CN (1) CN101516401A (es)
AU (1) AU2007286855A1 (es)
BR (1) BRPI0715864A2 (es)
CA (1) CA2661558A1 (es)
MX (1) MX2009001937A (es)
RU (1) RU2009110099A (es)
WO (1) WO2008024677A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009052559A1 (en) * 2007-10-22 2009-04-30 Melbourne Health A diagnostic assay
RU2639509C2 (ru) * 2011-06-27 2017-12-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. МикроРНК - БИОМАРКЕРЫ, УКАЗЫВАЮЩИЕ НА БОЛЕЗНЬ АЛЬЦГЕЙМЕРА
WO2014183023A1 (en) 2013-05-09 2014-11-13 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
CN106030310B (zh) 2013-12-13 2019-01-04 通用医疗公司 可溶性高分子量(hmw)tau种类及其应用
WO2016033160A2 (en) 2014-08-26 2016-03-03 The General Hospital Corporation Methods for controlling cell fate and consequences for disease
US11725232B2 (en) * 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
EP3794345B1 (en) 2018-05-18 2025-02-26 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
CN112684174B (zh) * 2021-01-21 2022-05-24 四川大学华西第二医院 Linc00305自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN114748612B (zh) * 2022-04-11 2023-07-14 南通大学 β半乳糖苷α-2,3-唾液酸转移酶3的药物新用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273661A1 (en) * 2000-06-30 2002-01-14 Duke University Methods of screening for alzheimer's disease
EP1203584A1 (en) * 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil)
EA009668B1 (ru) * 2003-03-19 2008-02-28 Арес Трейдинг С.А. Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
AU2005204358B2 (en) * 2004-01-05 2008-09-04 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate Alzheimer's disease
KR20060124712A (ko) * 2004-02-20 2006-12-05 노파르티스 아게 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제

Also Published As

Publication number Publication date
JP2010501186A (ja) 2010-01-21
EP2056876A1 (en) 2009-05-13
RU2009110099A (ru) 2010-09-27
CA2661558A1 (en) 2008-02-28
BRPI0715864A2 (pt) 2013-07-30
KR20090041447A (ko) 2009-04-28
WO2008024677A1 (en) 2008-02-28
US20100249107A1 (en) 2010-09-30
AU2007286855A1 (en) 2008-02-28
CN101516401A (zh) 2009-08-26

Similar Documents

Publication Publication Date Title
MX2009001937A (es) Biomarcadores para el progreso de la enfermedad de alzheimer.
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2009117122A8 (en) Genetic analysis
DE602006004251D1 (de) Instrument für Endoscope und Instrumentsystem für Endoscope.
TW200740844A (en) Novel MAdCAM antibodies
WO2011064225A8 (en) Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
EP1766077A4 (en) GENES AND PATHWAYS DIFFERENTIALLY EXPRESSED IN BIPOLAR DISORDERS AND / OR MAJOR DEPRESSIVE DISORDERS
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2007028162A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
ZA200710910B (en) Methods for the assessment of risk of developing lung cancer using analysis of genetic polymorphisms
WO2007120955A3 (en) Genes affecting human memory performance
EP1948831A4 (en) ALZHEIMER ASSOCIATED GENETIC POLYMORPHISMS, DETECTION METHOD AND USE THEREOF
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2009087689A3 (en) Novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
WO2007095352A3 (en) Diagnosis and treatment of attentional disorders
ATE424469T1 (de) Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung
WO2012006534A3 (en) Methods, compositions and kits for diagnosing and treating alzheimer's disease using mitochondrial co3 gene mutations
WO2006097462A3 (en) Compositions and methods for treating inflammatory cns disorders
WO2007022041A3 (en) Mutations and polymorphisms of hdac3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal